A Phase III study has found a trivalent hepatitis B virus (HBV) vaccine demonstrated superiority in adults 45 years and older and noninferior in adults older than 18 years compared with a monovalent vaccine.
Researchers have found combining immune tolerance induction (ITI) with Hemlibra (emicizumab, Roche) is a feasible and safe way of treating children with severe hemophilia A.
A new study shows cardiovascular outcomes may improve in individuals with hypertension if they receive the influenza (flu) vaccine during the flu season.
Researchers at the University of Rochester Medical Center in New York City have developed a new type of skin patch that could replace needles as a method to deliver the influenza (flu) vaccine.
The U.S. Food and Drug Administration (FDA) has approved WILATE for treatment of adults and adolescents with hemophilia A for routine prophylaxis.
A new study that looked at how the influenza (flu) virus escapes antibodies found the site of the escape mutation varies among most individuals’ sera.
The U.S. Food and Drug Administration (FDA) has approved Ziextenzo (pegfilgrastim-bmez), the 24th biosimilar approval in the U.S.
The Centers for Medicare and Medicaid Services (CMS) has launched the Healthy Adult Opportunity (HAO) optional demonstration initiative to give states tools to design innovative health coverage programs for adult beneficiaries, while holding states accountable for results and maintaining strong protections for the most at-risk populations.
The Centers for Medicare and Medicaid Services (CMS) finalized a decision to cover acupuncture for Medicare patients with chronic low back pain.
New rule requires hospitals to share previously obscured price information, including discounts for cash-paying patients and rates negotiated with insurers.
The U.S. Food and Drug Administration (FDA) is taking critical actions to advance development of novel coronavirus medical countermeasures.
The awards establish and provide up to seven years of support for three Immune Mechanisms of Protection Against Mycobacterium Tuberculosis (IMPAc-TB) Centers to elucidate the immune responses needed to protect against Mtb infection.
